Blair William & CO Supernus Pharmaceuticals, Inc. Transaction History

Blair William & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$23.54 - $31.39 $10,357 - $13,811	-440 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$26.72 - $33.19 $4,008 - $4,978	-150 Reduced 25.42%	440 $14,000
Q1 2021 May 13, 2021	BUY	$24.15 - $31.45 $2,777 - $3,616	115 Added 24.21%	590 $15,000
Q4 2020 Feb 09, 2021	BUY	$17.7 - $25.81 $885 - $1,290	50 Added 11.76%	475 $12,000
Q3 2020 Nov 06, 2020	BUY	$20.2 - $25.05 $2,727 - $3,381	135 Added 46.55%	425 $9,000
Q2 2020 Aug 12, 2020	SELL	$17.09 - $24.89 $4,016 - $5,849	-235 Reduced 44.76%	290 $7,000
Q1 2020 May 11, 2020	SELL	$14.45 - $24.69 $16,617 - $28,393	-1,150 Reduced 68.66%	525 $9,000
Q4 2019 Feb 13, 2020	BUY	$19.93 - $29.13 $33,382 - $48,792	1,675 New	1,675 $40,000
Q1 2018 May 15, 2018	SELL	$37.15 - $46.9 $415,002 - $523,919	-11,171 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$36.4 - $42.6 $151,460 - $177,258	4,161 Added 59.36%	11,171 $445,000
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $257,617 - $348,046	7,010	7,010 $280,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.